Skip to content

US · VMD · MEDICAL - CARE FACILITIES

Viemed Healthcare, Inc. (VMD) intrinsic value and stock valuation

$8.52as of 2026-11-21 · Mkt cap 376.47M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Viemed Healthcare, Inc. DCF and intrinsic value

InvestorsCraft values VMD with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from VMD’s statements →

Viemed Healthcare, Inc. Graham Number

Graham Number: $5.65d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Care Facilities Lafayette, LA 70508 viemed.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$270.3M+15.5% 5y CAGRd
20142025
Net income
$14.9M-13.9% 5y CAGRd
20142025
Free cash flow
$11.9M-11.6% 5y CAGRd
20142025
Total equity
$143.5M+11.9% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$270.3M$224.3M$183M$138.8M$117.1M
Operating income$20.7M$17.9M$14.3M$8.25M$11.6M
Net income$14.9M$11.3M$10.2M$6.22M$9.13M
EPSd$365.8K$276.2K$253.6K$156.2K$224.4K
Operating cash flow$51.9M$39.1M$45.2M$27.8M$22.5M
Capital expenditure-$-39.98M-$-37.77M-$-26.09M-$-22.9M-$-19.74M
Free cash flow$11.9M$1.32M$19.1M$4.85M$2.75M
Total assets$214.9M$177.1M$154.9M$117M$118M
Total debt$16M$6.87M$10.3M$690K$6.52M
Net debt$2.45M-$-10.67M-$-2.52M-$-16.22M-$-21.89M
Total equity$143.5M$133.3M$113.9M$97.1M$94.8M
Cash and short-term investments$13.5M$17.5M$12.8M$16.9M$28.4M
Income statement
20252024202320222021
Revenue$270.3M$224.3M$183M$138.8M$117.1M
Cost of revenue$114.8M$91.1M$70.2M$54.2M$43.7M
Gross profit$155.5M$133.2M$112.8M$84.7M$73.4M
Research and development expenses$3.02M$3.07M$2.78M$2.7M$2.11M
Selling, general and administrative expenses$130.5M$112.5M$93.7M$73.4M$60M
Other expenses$1.23M-$-250K$1.94M$370K-$-320K
Operating expenses$134.8M$115.3M$98.5M$76.4M$61.8M
Cost and expenses$249.6M$206.4M$168.7M$130.6M$105.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$1.18M$780K$420K$200K$320K
Depreciation and amortization$28.6M$25.4M$21.9M$15.6M$11.3M
Ebitda$51.6M$42.3M$36.7M$24.8M$24.1M
Operating income$20.7M$17.9M$14.3M$8.25M$11.6M
Total other income/expenses, net$1.06M-$-1.73M$60K$740K$920K
Income before tax$21.8M$16.2M$14.4M$8.99M$12.5M
Income tax expense$6.39M$4.76M$4.15M$2.77M$3.38M
Net income$14.9M$11.3M$10.2M$6.22M$9.13M
Weighted average shares outstanding$38.9M$38.8M$38.4M$38.7M$39.5M
Weighted average diluted shares outstanding$40.8M$40.8M$40.4M$39.8M$40.7M
Balance sheet
20252024202320222021
Cash and short-term investments$13.5M$17.5M$12.8M$16.9M$28.4M
Net receivables$25.6M$24.9M$18.5M$15.4M$14.7M
Inventory$5.05M$4.32M$4.63M$3.57M$2.46M
Total current assets$48.5M$52.9M$38.4M$39.7M$47.3M
Property, plant and equipment, net$82.4M$79.2M$76.9M$68.4M$62.9M
Goodwill and intangible assets$60.2M$33.8M$30.3M$0.00$0.00
Long-term investments$2.79M$2.79M$3.9M$4.16M$2.16M
Total non-current assets$166.5M$124.2M$116.5M$77.3M$70.7M
Total assets$214.9M$177.1M$154.9M$117M$118M
Accounts payable$12.3M$9.34M$7.41M$4.9M$5.25M
Short-term debt$2.29M$1.27M$2.01M$490K$1.94M
Deferred revenue$7.52M$6.69M$6.21M$4.62M$3.75M
Total current liabilities$41.1M$37.3M$32.1M$18.9M$17.8M
Long-term debt$13.7M$5.6M$8.32M$200K$4.57M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$30.4M$6.44M$8.88M$1.09M$5.33M
Capital lease obligations$3.57M$2.87M$3.25M$690K$730K
Total liabilities$71.4M$43.8M$41M$20M$23.1M
Common stock$16.9M$23.4M$18.7M$15.1M$14M
Retained earnings$102.9M$89.7M$79.5M$69.9M$73.3M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$-280K
Total equity$143.5M$133.3M$113.9M$97.1M$94.8M
Total investments$2.79M$2.79M$3.9M$4.16M$2.16M
Total debt$16M$6.87M$10.3M$690K$6.52M
Net debt$2.45M-$-10.67M-$-2.52M-$-16.22M-$-21.89M
Cash flow statement
20252024202320222021
Net income$14.9M$11.4M$10.2M$6.22M$9.13M
Depreciation and amortization$28.6M$25.4M$21.9M$15.6M$11.3M
Stock-based compensation$9.13M$6.29M$5.85M$5.2M$5.15M
Change in working capital-$-2.3M$350K$7.78M-$-10.13M-$-13.56M
Accounts receivable$1.16M-$-6.07M-$-1.08M-$-12.57M-$-7.34M
Inventory$60K$570K-$-480K$300K-$-210K
Accounts payable$480K$360K-$-870K-$-320K$130K
Net cash provided by operating activities$51.9M$39.1M$45.2M$27.8M$22.5M
Investments in property, plant and equipment-$-39.98M-$-37.77M-$-26.09M-$-22.9M-$-19.74M
Acquisitions, net-$-26.33M-$-3M-$-28.59M-$-140K-$-600K
Net cash used for investing activities-$-50.17M-$-30.7M-$-52.11M-$-23.98M-$-19.75M
Common stock issued$1.44M$0.00$0.00$0.00$0.00
Common stock repurchased-$-13.22M-$-1.07M-$-590K-$-9.71M-$-1.43M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-5.79M-$-3.69M$2.83M-$-15.27M-$-5.32M
Net change in cash-$-4.04M$4.7M-$-4.08M-$-11.49M-$-2.57M
Cash at end of period$13.5M$17.5M$12.8M$16.9M$28.4M
Operating cash flow$51.9M$39.1M$45.2M$27.8M$22.5M
Capital expenditure-$-39.98M-$-37.77M-$-26.09M-$-22.9M-$-19.74M
Free cash flow$11.9M$1.32M$19.1M$4.85M$2.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Viemed Healthcare, Inc.

        Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

        CEO
        Casey Hoyt
        Employees
        1.38K
        Beta
        1.10

        Explore

        Frequently asked questions

        What is the intrinsic value of Viemed Healthcare, Inc. (VMD)?

        Viemed Healthcare, Inc. (VMD) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is VMD undervalued?

        VMD trades at a price of $8.52 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.